The White House published a factual list on September 18, saying that President Trump announced that Medicaid programs in 50 states across the US will be included in the “most-favoured-nation” prescription drug pricing system, and that pharmaceutical companies must use rebates to ensure that the final Medicaid payment price is not higher than the lowest price in other developed countries. The model covers hundreds of branded drugs, covering major drug categories such as cancer, diabetes, and asthma. As a result, the Medicaid program has received 1 million free prescriptions for the heart disease drug Eliquis. The White House Council of Economic Advisers estimates that the policy will save 64.3 billion US dollars in drug costs over the next ten years, of which the federal government will save 36.6 billion US dollars and the state government will save 27.6 billion US dollars; the CEA also estimates that the total savings brought by the MFN agreement over the next ten years will reach 600 billion US dollars.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.